Press releases

Emplicure's patch technology receives US patent approval

The United States Patent and Trademark Office granted a patent to Emplicure on 9th April 2019 for its patch technology. This patent provides protection for Emplicure's transdermal patch with abuse deterrent properties for the treatment of chronic pain until September 2031.

"Both USA and Europe are important markets for Emplicure and to get approvals of patent applications in these territories are important steps in the product and business development", says Susanne Bredenberg, CEO at Emplicure.

The protection provided by this patent should extend to future, related products that are in development based on this technology. A patent for this technology was also granted by the European Patent Office in 2017.

For more information, please contact:

Susanne Bredenberg, CEO Emplicure

Phone: + 46 (0)70 859 77 99


About Emplicure

Emplicure is a research and development focused pharmaceutical company based in Uppsala, Sweden. The company develops new patentable pharmaceutical products based on drug delivery platform technologies originating from the interface between the materials and pharmaceutical sciences. Emplicure currently has several products in the pipeline in formulation or preclinical development phase. The first product to enter the clinical phase is a transdermal patch with abuse deterrent properties for the treatment of chronic pain. The products will be sold or out licensed at different development stages to larger pharmaceutical companies.


Idag, måndagen den 7 juni 2021, inleds teckningsperioden för teckning av units inför den planerade noteringen av Emplicure AB (publ)s ("Emplicure" eller "Bolaget") aktier på Nasdaq First North Growth Market. Teckningsperioden löper fram till och med torsdagen den 17 juni 2021.


Emplicure AB (publ) ("Emplicure" eller "Bolaget") har upprättat ett prospekt avseende den förestående nyemissionsn av units i samband med den planerade noteringen av Bolagets aktier på Nasdaq First North Growth Market ("Erbjudandet" respektive "Nasdaq First North"). Tillväxtprospektet finns tillgängligt på Bolagets webbplats,, samt kommer finnas tillgängligt på Mangold Fondkommissions webbplats,


Styrelsen i Emplicure AB (publ) ("Emplicure" eller "Bolaget") offentliggör idag sin avsikt att genomföra en notering av Bolagets aktier på Nasdaq First North Growth Market ("Nasdaq First North"). I anslutning till noteringen genomför Bolaget en unitemission om cirka 39,8 MSEK, där varje unit består av en (1) aktie och en (1) vederlagsfri teckningsoption av serie TO1 ("Erbjudandet").


Emplicure has completed funding of 11,75 MSEK through convertibles.


Emplicure was selected as one of the bests Scandinavian startups in the European HealthCatapult (EHC) programme. They will now be one of the companies to represent EIT Health Scandinavia in the semifinals in Europe. In the first selection round held in Stockholm the 27th of May Susanne Bredenberg, CEO of Emplicure, was pitching in front of an experienced jury.



Recieve press releases and reports via email.